Udifitimod

Udifitimod (BMS-986166) is a potent, selective and orally active S1P1R modulator. Udifitimod has the potential for the research of autoimmune diseases[1][2].

Product Specifications

CAS Number

[1883345-06-9]

Product Name Alternative

BMS-986166

UNSPSC

12352005

Target

LPL Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/udifitimod.html

Solubility

10 mM in DMSO

Smiles

OC[C@]1(N)C[C@@H](C2=CC=C3C[C@H](CCC4=CC=CC=C4OC)CCC3=C2)CC1

Molecular Formula

C25H33NO2

Molecular Weight

379.54

References & Citations

[1]Bihorel S, et al. Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan;10 (1) :8-21.|[2]Gilmore JL, et al. Identification and Preclinical Pharmacology of ((1 R,3 S) -1-Amino-3- ((S) -6- (2-methoxyphenethyl) -5,6,7,8-tetrahydronaphthalen-2-yl) cyclopentyl) methanol (BMS-986166) : A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials. J Med Chem. 2019 Mar 14;62 (5) :2265-2285.